EtelcalcetideCalcimimetic peptide
Etelcalcetide helps control overactive parathyroid signalling in adults receiving haemodialysis. It makes the parathyroid glands more sensitive to calcium, rather than replacing calcium or parathyroid hormone.
What is Etelcalcetide?
Etelcalcetide is a calcimimetic used for secondary hyperparathyroidism in adults with chronic kidney disease receiving haemodialysis. 3
How it works
It activates the calcium-sensing receptor, reducing parathyroid-hormone secretion. Blood calcium can also fall as part of its pharmacological effect. 3
Effects studied
Parathyroid-hormone reduction
The EMA assessment describes PTH reductions in studies comparing etelcalcetide with placebo and cinacalcet. 3
Evidence: Clinical evidence for biochemical control; it does not by itself establish fewer fractures or longer survival.
What does the evidence show?
Randomised PTH-control trials and EMA assessment
When the calcium control system becomes overactive
Advanced kidney disease disrupts the balance between calcium, phosphate and parathyroid hormone, or PTH. The parathyroid glands can respond by producing too much hormone. Etelcalcetide addresses this secondary hyperparathyroidism in a setting where blood results and dialysis care are assessed together.
How the signal is changed
Etelcalcetide activates the calcium-sensing receptor on parathyroid cells. This tells the gland to release less PTH and can also lower blood calcium. It is therefore quite different from PTH replacement medicines used when the hormone is missing. The similar names describe opposite aims: reducing excess hormone activity or replacing a missing hormone.
What the trials establish
The EMA assessment describes trials in adults on haemodialysis, with reductions in PTH as a principal outcome. Comparisons included placebo and the oral calcimimetic cinacalcet. Better control of a laboratory measure does not, by itself, quantify effects on fractures, cardiovascular events or survival. 3
Why calcium monitoring is needed
Calcium can fall too far. Muscle spasms and gastrointestinal symptoms are among the reported adverse effects, and low calcium requires clinical attention. Parsabiv is an EU-authorised medicine for this specific dialysis population; it is not a calcium-balancing supplement for otherwise healthy people. 3
Safety & status
Hypocalcaemia, muscle spasms and gastrointestinal effects are important considerations. Calcium monitoring is part of treatment. 3
Country and product status
EU Parsabiv indication checked: secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis. Swiss status not checked.
Frequently asked questions
Is this a medicine for low calcium?
No. It treats excessive PTH in a specific dialysis setting and can itself lower calcium. 3
Does lower PTH prove fewer fractures?
No. PTH control and fracture prevention are different outcomes; the evidence summarised here concerns biochemical control. 3
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Retained paper reference Archive research lead · Retained archive reference; not independently checked for this draft
- Retained source reference Archive research lead · Retained archive reference; not independently checked for this draft
- EMA · Parsabiv assessment Primary source checked · Checked 27 October 2026: haemodialysis indication, PTH trial endpoints, mechanism and hypocalcaemia risk.
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.